Business
GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R)
Company Aligns Resources With Programs Demonstrating Strong Clinical, Regulatory, and Market Momentum ATLANTA, GA - May 26, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and ...
About this update from Geovax Labs, Inc.
[{"type":"image","caption":"","headline":"GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R)","size":{"original":{"width":140,"height":140,"url":"https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CXbp4KTqODofEIjT8dXa7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMA--/https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc","width":140,"height":140},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/CXbp4KTqODofEIjT8dXa7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMA--/https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc","width":140,"height":140}}},{"type":"text","content":"Company Aligns Resources With Programs Demonstrating Strong Clinical, Regulatory, and Market Momentum","length":101,"tagName":"p"},{"type":"text","content":"ATLANTA, GA - May 26, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines, today announced a strategic prioritization of its development portfolio to concentrate resources on its lead programs, GEO-MVA and Gedeptin(R), reflecting increasing clinical, regulatory, and market alignment across these programs. As part of this decision, the Company has elected to discontinue active development activities related to its GEO-CM04S1 COVID-19 vaccine candidate. This decision was not related to any safety concerns with the vaccine but reflects the continued evolution and contraction of the global COVID-19 vaccine market, and GeoVax's focus on programs with clearer regulatory pathways, stronger demand visibility, and more immediate commercialization potential. GeoVax emphasized that portfolio prioritization is a standard and essential practice within the biotechnology industry, enabling companies to align resources with the highest-value opportunities as market conditions and scientific landscapes evolve.","length":1095,"tagName":"p"},{"type":"text","content":""GeoVax is at an important inflection point, and this decision reflects a deliberate and disciplined focus on the programs we believe can deliver the greatest near-term and long-term value," said David Dodd, Chairman and Chief Executive Officer of GeoVax. "As GEO-MVA advances toward clinical validation and potential co...